Physician profile
Jonathan Da Costa
NPI 1275890170
$73,551.21
in general payments reported to CMS, 2019-2025
31 companies · $30K in 2025
The $30K reported for 2025 was more than what 98% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,214 · 2020: $428 · 2021: $1,178 · 2022: $18K · 2023: $16K · 2024: $7,219 · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $44K · Food and Beverage: $8,535 · Travel and Lodging: $305 · Education: $65.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $43,847.50 |
| Food and Beverage | $8,535.19 |
| Travel and Lodging | $304.99 |
| Education | $65.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $47,719.87 | 2021-2025 | |
| Akebia Therapeutics INC | $15,887.37 | 2019-2025 | Vafseo, Auryxia |
| Mallinckrodt Hospital Products INC. | $1,807.88 | 2020-2025 | Acthar, Terlivaz |
| Amgen INC. | $1,296.68 | 2019-2025 | Krystexxa, Tavneos |
| Astrazeneca Pharmaceuticals LP | $1,248.65 | 2019-2025 | Farxiga, Lokelma |
| Horizon Therapeutics Plc | $774.57 | 2021-2023 | Krystexxa |
| Opko Pharmaceuticals, LLC | $579.60 | 2019-2025 | Rayaldee |
| Aurinia Pharma U.S., INC. | $553.53 | 2021-2025 | Lupkynis |
| Calliditas Therapeutics US INC. | $406.41 | 2022-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $404.11 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $322.30 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $295.68 | 2021-2024 | Veltassa |
| Scpharmaceuticals INC. | $276.27 | 2025 | |
| Mallinckrodt Enterprises LLC | $275.53 | 2019 | |
| Novartis Pharmaceuticals Corporation | $259.45 | 2019-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $236.61 | 2024-2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $192.46 | 2023-2025 | Purified Cortrophin Gel |
| Fresenius USA Marketing, INC. | $190.43 | 2022-2025 | Velphoro, Velphoro |
| Glaxosmithkline, LLC. | $150.16 | 2021-2023 | Benlysta, Jesduvroq |
| Lilly USA, LLC | $139.78 | 2019-2023 | Jardiance |
| Ardelyx, INC. | $120.90 | 2023-2025 | Ibsrela |
| Nxstage Medical, INC. | $118.64 | 2024 | |
| Kyowa Kirin, INC. | $78.67 | 2023-2024 | Crysvita |
| Novo Nordisk INC | $78.32 | 2025 | Ozempic, Rybelsus |
| Mannkind Corporation | $39.59 | 2025 | |
| One Lambda, INC. | $24.61 | 2025 | |
| Baxter Healthcare | $22.72 | 2021 | |
| Apellis Pharmaceuticals, INC. | $17.72 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $16.94 | 2021 | |
| Cycle Pharmaceuticals INC | $15.76 | 2025 | Venxxiva |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Da Costa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.